Avitinib

02/20

ALTERNATE NAMES: Abivertinib; N-[3-[[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; AC0010

CATALOG #:

B2995-5	5 mg
B2995-25	25 mg

STRUCTURE:



MOLECULAR FORMULA: $C_{26}H_{26}FN_7O_2$

MOLECULAR WEIGHT: 487.53

CAS NUMBER: 1557267-42-1

APPEARANCE: White to off-White Powder

PURITY: >98%

SOLUBILITY: ~30 mg/ml in DMSO, ethanol, DMF

DESCRIPTION: Avitinib is a pyrrolopyrimidine-based, irreversible inhibitor of the epidermal growth factor receptor (EGFR) receptor tyrosine kinase. It inhibits EGFR L858R/T790M double mutations with an IC_{50} value of 0.18 nM which is nearly 43-fold potent over wild-type EGFR (IC_{50} value of 7.68 nM) in kinase assays. In a xenograft model, oral administration at a daily dose of 500 mg/kg results in complete remission of tumors with EGFR-active and T790M mutations.

STORAGE TEMPERATURE: -20ºC. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Xu, X., Mao, L., Xu, W., et al. AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients. Mol. Cancer Ther. 15(11), 2586-2597 (2016).

RELATED PRODUCTS:

ZM306416 (Cat. No. B2915)
BIBW2992 (Tovok) (Cat. No. 1616)
HDAC, EGFR & HER2 inhibitor (Cat. No. B2933)
WZ-8040 (Cat. No. B2205)
EZSolution™ AZD-9291 (Osimertinib) (Cat. No. B2490)

DISCLAIMER: ***FOR RESEARCH USE ONLY! Not to be used on humans.***